Applied Therapeutics announced that it will present full results from the Phase 3 ARISE-HF study evaluating AT-001 caficrestat in Diabetic Cardiomyopathy DbCM in an oral presentation at the 2024 American College of Cardiology ACC Annual Scientific Session to take place April 6-8, 2024 in Atlanta, Georgia. The Company announced topline results from ARISE-HF in January 2024, demonstrating a strong trend in stabilizing cardiac functional capacity with AT-001 treatment, and a statistically significant difference in cardiac functional capacity in a prespecified subgroup of patients not receiving concomitant treatment with an SGLT2 or GLP-1 while preventing clinically significant worsening. The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures. AT-001 treatment prevented progression to overt heart failure in patients with DbCM as compared to placebo. Detailed safety data will also be presented, demonstrating that AT-001 was safe and well tolerated in a large cohort of patients, providing proof of concept that the technology has overcome the selectivity and safety issues of “old” aldose reductase inhibitors. The oral presentation at ACC will be followed by simultaneous publication of the study results in the Journal of the American College of Cardiology Journal JACC.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics down 11% after extended FDA review for govorestat NDA
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics: FDA extends review period for NDA for govorestat
- Applied Therapeutics initiated with an Outperform at RBC Capital
- Applied Therapeutics files to sell 14.29M shares of common stock for holders